Overview:

CRISPR-Cas systems constitute the adaptive immune system in bacteria via RNA-guided endonucleases (1,2). This system has been redesigned to create an exemplary genome editing tool for application to RNA-based therapeutics development (3). PsmCas13b (Prevotella sp. MA2016 Cas13b) is a CRISPR-Cas effector that belongs to the class 2 subtype VI-B, and has been shown to effectively target and silence distinct mammalian ssRNA viruses (3,4). Cas13b processes its own CRISPR array with short and long direct repeats, cleaves target RNA, and exhibits collateral RNase activity (4).

Gene Aliases:

None

Genbank Number:

WP_028912271

References:

1. Horvath, P., et al. CRISPR/Cas, the immune system of bacteria and archaea. Science, 327(5962):167-170. 2. Morange, M. What history tells us XXXVII. CRISPR-Cas: The disconvery of an immune system in prokaryotes. J. Biosci. 40(2):221-223. 3. Smargon, A. A., et al. Cas13b is a Type VI-B CRISPR-associated RNA-Guided RNAse differentially regulated by accessory proteins Csx27 and Csx28. Mol. Cell. 65(4):618-630. 4. Freije, C. A., et al. Programmable Inhibition and Detection of RNA Viruses Using Cas13. Mol. Cell. 76(5):826-837.